Projects

For children with rhabdomyosarcoma, assessing response to treatment and whether they remain in remission requires regular imaging such as MRI. In some types of cancer, but not rhabdomyosarcoma, it has been shown to be clinically useful to assess abnormal DNA released from a cancer into the blood stream.

Thirty five thousand children, adolescents and young adults are diagnosed with cancer every year in Europe; among them 20% will not be cured. This projects aims at understanding the resistance mechanisms in the event of inefficacy of the first line treatments.

This innovative clinical trial will test the combination of three classical metronomic chemotherapies with a PD-1 checkpoint inhibitor or Nivolumab®.

This project consists in the financing of the salary of a data manager during three years and will result in the thorough analysis of data collected during a major clinical trial.